Estimated market cap $33.00BShares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily. This figure: shares as of Dec 31, 2025, last close Nov 13, 2026.642.38M ADSs, shares as of Dec 31, 2025CIK 1434265The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
—
No open-market trades
Congress trades, 24 mo
3
2 purchases, 1 sale
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in Genmab A/S's latest quarterly report, compared with the one before.
We have not read a recent 10-Q for this company yet.
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What Genmab A/S and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
224
87 added · 55 trimmed
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
No recent insider purchases or sales for this company.
13F holders
39.22M shares
224 funds report GMAB. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Q3 2026. 49 new, 87 added to, 55 trimmed, 116 exited since Q2 2026.
Download CSVEvery fund that holds GMAB, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
3 in 24 mo
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Recent congressional trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
What Genmab A/S and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report, adjusted for splits
Funds holding the stock by quarter
Q1 2014
1
—
580
$2,000
Q2 2014
1
0
625
$3,000
Q3 2014
1
0
2,225
$9,000
Q2 2016
2
+1
19,190
$350.5K
Q3 2016
2
0
16,420
$280.5K
Q4 2016
3
+1
91,715
$1.5M
Q1 2017
3
0
120,775
$2.3M
Q2 2017
4
+1
181,275
$3.9M
Q3 2017
5
+1
215,880
$4.8M
Q4 2017
4
-1
225,395
$3.7M
Q1 2018
5
+1
424,200
$9.2M
Q2 2018
5
0
437,691
$6.7M
Q3 2018
7
+2
315,789
$5.0M
Q4 2018
6
-1
342,843
$5.6M
Q1 2019
7
+1
1.04M
$18.7M
Q2 2019
7
0
1.09M
$20.7M
Q3 2019
97
+90
25.20M
$511.0M
Q4 2019
133
+36
23.72M
$565.3M
Q1 2020
143
+10
28.75M
$645.4M
Q2 2020
175
+32
37.98M
$1.3B
Q3 2020
199
+24
40.94M
$1.5B
Q4 2020
227
+28
42.52M
$1.7B
Q1 2021
210
-17
41.82M
$1.4B
Q2 2021
213
+3
46.17M
$1.9B
Q3 2021
213
0
42.77M
$1.9B
Q4 2021
211
-2
39.81M
$1.6B
Q1 2022
203
-8
35.49M
$1.3B
Q2 2022
181
-22
35.55M
$1.2B
Q3 2022
194
+13
44.42M
$1.4B
Q4 2022
238
+44
46.43M
$2.0B
Q1 2023
217
-21
43.97M
$1.6B
Q2 2023
214
-3
41.70M
$1.6B
Q3 2023
234
+20
47.51M
$1.7B
Q4 2023
226
-8
47.86M
$1.5B
Q1 2024
227
+1
49.93M
$1.5B
Q2 2024
220
-7
48.77M
$1.2B
Q3 2024
224
+4
52.32M
$1.3B
Q4 2024
230
+6
60.88M
$1.3B
Q1 2025
220
-10
64.92M
$1.3B
Q2 2025
219
-1
63.87M
$1.3B
Q3 2025
256
+37
61.95M
$1.9B
Q4 2025
295
+39
73.30M
$2.3B
Q1 2026
277
-18
81.91M
$2.2B
Q2 2026
291
+14
102.29M
$2.8B
Q3 2026
224
-67
39.22M
$1.4B
Each point is a quarter-end, from Q1 2014 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (372303206). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2014) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits (5-for-1 on May 1, 2018): reports from before a split are multiplied by its ratio, so every quarter is on the share count of Q3 2026.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.